JOSEP CARRERAS FOUNDATION
This year we were able to count on the support of two new sponsors for the main event of 'patients' day', which was held on 18 June in Barcelona. The pharmaceutical companies Novartis and Takeda have lent their support to the initiative for the first time. We hope that these agreements will make it possible to strengthen and develop the alliance with both of them in the future.
We would like to share with you some videos that show the most important moments in our campaign.
The video shows some of the events of 18 June when almost a thousand patients and former patients for leukaemia or other malignant blood diseases took to the streets throughout Spain to raise awareness of these diseases and to encourage people to send a fund-raising SMS message. In this clip you can see what happened in Barcelona at the convent of Sant Agustí.
And a special mention is deserved by all those people who, by sending an SMS message, making a donation or by organising a fund-raising event for our Foundation, made it possible for us to achieve our aim of raising €150,000 to buy the equipment needed by Dr. Javier Briones and his team at the Sant Pau Campus. To everyone who has helped us and all of you who work every day to make progress in the fight against leukaemia, a very big THANK YOU.
The Foundation's Activities Report is now available. In it you can see what we have managed to achieve between us. Together we are UNSTOPPABLE against leukaemia!
Click HERE to read it.
JOSEP CARRERAS LEUKAEMIA RESEARCH INSTITUTE
Paper by Dr. Maria Joao Baptista published in Nature Communications
The paper that has been published is entitled, 'Homeobox NKX2-3 promotes marginal-zone lymphomagenesis by activating B-cell receptor signalling and shaping lymphocyte Dynamics' and is the fruit of collaboration with Dr. José Ángel Martínez-Climent of the Hemato-oncology division of the Centre for Applied Medical Research (CIMA).
We had an interview with Dr. Baptista in which she described the project that has been published in Nature Communications in more detail, and we learnt more about her research clinic at the IJC. Don't miss it! Click HERE.
Dr. Pablo Menéndez's group awarded a RETOS project grant
The IJC stem cell and cancer group led by Dr. Pablo Menéndez has been awarded a grant by the Ministry of Science and Technology for the RETOS project with companies in the field of technological innovation. Our Institute has received €123,000 from the company ENTRECHEM S.L. (coordinator of the study and drug patent owner) for the study of new kinase inhibitors in acute myeloid leukaemia (AML) with FLT3 gene mutation, a mutation associated with a poor prognosis.
Dr. Francesc Solé's team publishes a paper in the journal Blood about myelodysplastic syndromes (MDS) entitled, 'Time-dependent changes in mortality and transformation risk in MDS'
In myelodysplastic syndromes (MDS) evolution of risk for disease progression or death has not been systematically investigated despite being crucial for correct interpretation of prognostic risk scores. In a multicentre retrospective study they describe changes in risk over time, the consequences for basal prognostic scores and their potential clinical implications. Major MDS prognostic risk scoring systems (IPSS, IPSS-R, WPSS, LR-PSS) and their constituent individual predictors were analysed in 7,212 primary untreated MDS patients from the IWG-PM database. Changes in risk of mortality and of leukemic transformation over time from diagnosis were described. In higher risk MDS, hazards regarding mortality and AML transformation diminished over time from diagnosis, whereas they remained stable in lower risk patients. After approximately 3.5 years, hazards in the separate risk groups became similar and essentially equivalent after five years. This fact led to loss of prognostic power of different scoring systems considered – more pronounced for survival. Inclusion of age resulted in increased initial prognostic power for survival and less attenuation in hazards. If needed for practicability in clinical management the differing development of risks suggested a reasonable division into lower and higher risk MDS based on the IPSS-R at a cut-off of 3.5 points. Our data regarding time-dependent performance of prognostic scores reflect the disparate change of risks in MDS subpopulations. Lower risk patients at diagnosis remain “constant lower risk", while "initially high risk" patients demonstrate decreasing risk over time. This change of risk should be considered in clinical decision making.
Raúl Torres, researcher in Stem Cell, Mesenchymal Cancer and Development Group at the University of Barcelona Hospital Clínic Campus has just been awarded financial support by the Lady Tata Memorial Trust to continue with his project at our centre
On hearing this great news we wanted to talk with Raul Torres about his work as a researcher specialised in the study of DNA, cell biology and genome engineering. You can read what he had to say HERE.
The new building for the Catalan Institute of Oncology/Germans Trias i Pujol Campus approaches the final stage!
During the months of June and July great progress was made in both the building work and the installations.
Work on the interior is focused on putting the finishing touches to the auditorium wall coverings and the Atrium at the ground-floor level as well as general work on the fixed furniture such as the reception desk, the counters in the coffee corners as well as other work of a general nature such as painting and ceiling installation, adjustments and revision and so forth.
The facades on the exterior of the building have been finished and work is currently focused on general aspects of the entrance to the building via the square (waterproofing and paving) and putting the finishing touches to the covered gardened area on the third floor with its wooden paving and planted areas.
Some of the final installations remain to be finished such as the installation of light fittings and electrical equipment and decorative elements. Final tests and some connections and adjustments are also pending.
Work on Phase 1 should be completed by the end of the summer and in the autumn work should begin on the Final Phase of equipping the building.
During the first six months of this year Spain achieved a total number of 230,000 bone marrow donors
Data from the National Transplant Organization (ONT) show that there were 22,431 new donors in the first six months of this year, more than planned to achieve the aim of 40,000 by the end of the year.
New donors are registering at the rate of 120 per day and this should make it possible to have more than a quarter of a million donors by the end of 2016.
At this rate the aim of achieving 400,000 donors by 2020 will be more than met.
A very special video
To mark this achievement and thank the donors the National Transplant Organization (ONT), REDMO and the Spanish Hematology and Hemotherapy Society (SEHH) have made this video. Click HERE.
Dining with the stars
Once again the Michelin-stared restaurants of Tarragona held a dinner to raise funds for the fight against for leukaemia and cancer at the Tarragona Educational Complex. This was the fifth dinner to be held. The event was supported by the Districts of Tarragona and Terres de l'Ebre Cancer Leagues and recently they donated the €3,583 raised to assist us with our mission to overcome leukaemia!
Fund-raising events.... unstoppable against leukaemia!
To mark Leukaemia Week there were 23 fund-raising events and they managed to raise a total of €38,983.44.
We would like to make a special mention of one of the events that managed to raise €20,615! It was the 1st Arturo Darch Memorial Gala Dinner that was held in Sotogrande, Cadiz. Tina Grau, who runs the Foundation's partners, deeds and inheritance department, attended this remarkable gala dinner, held at the facilities of the Royal Polo Club. The Malaga Symphony Orchestra accompanied the event with a performance of a selection of pieces of classical music.
Nit & Dia: artistic performance and fund raising
Tickets are sold out for the double fund-raising performance of the Nit & Dia group of the 'Cercle de Breda'!
Once again support comes from the hands of performing artists who, on this occasion, wanted to make their contribution in support of our projects by doing what they know best: performing.
The performance was in homage to the nephew of the artistic director, Mr. Joaquin.
Thank you to all those who made it possible to €6,049 for our cause.